bioMérieux Highlights Positive Impacts of Rapid, Accurate Diagnostics for Patients and Accepts Industry Awards at ADLM 2026
bioMérieux Highlights Positive Impacts of Rapid, Accurate Diagnostics for Patients and Accepts Industry Awards at ADLM 2026
PR Newswire
SALT LAKE CITY, Aug. 7, 2026
SALT LAKE CITY, Aug. 7, 2026 /PRNewswire/ -- bioMérieux, a world leader in the field of in vitro diagnostics, leveraged this year's 2026 Association for Diagnostics & Laboratory Medicine (ADLM) Annual Conference & Clinical Lab Expo for an important conversation about the impact of access to diagnostics while also accepting multiple IMV ServiceTrak™ awards.
PRESS CONFERENCE
The company hosted a press panel, The Power of Diagnostics: How Delays Impact Patients and Providers, to discuss the real-world impacts of delayed or inaccurate diagnostic answers for patients, providers, communities, and the healthcare system. Dr. Charles K. Cooper, Executive Vice President and Chief Medical Officer at bioMérieux, moderated the panel with:
- Dr. Omai Garner, Clinical Professor and Director of Clinical Microbiology, UCLA;
- Dr. Michael Astion, PhD, Medical Director, Regional Laboratories and Point of Care, Medical Director, Reference Laboratories and PLUGS (Patient-Centered Laboratory Utilization Guidance Services), Department of Laboratories, Seattle Children's Hospital, Professor of Laboratory Medicine and Pathology, University of Washington;
- Helaine Bader, MPH Vice President of Education, HealthyWomen; and
- Dr. John Hurst, Senior Director, Field Medical Affairs at bioMérieux.
Dr. Cooper noted that the panel discussed the "tremendous amount of pressure health care systems face and how access to rapid diagnostics at the point of care often alleviates some of this stress by getting health care clinicians and their patients answers while they wait."
"Delay in getting a diagnosis may result in patients not receiving treatment at all because they may not come back for follow-up," said Ms. Bader. "Faster time to diagnosis during a single visit not only provides the patient with immediate answers but also builds trust between the patient and provider and reduces patient frustration, potential complications from the infection and the need for repeat visits."
INDUSTRY RECOGNITION
During the show, bioMérieux also accepted seven 2026 IMV ServiceTrak™ Clinical Laboratory Awards. These awards highlight bioMérieux's continued commitment to delivering industry-leading diagnostic solutions and exceptional customer support to clinical laboratories.
2026 ServiceTrak Awards: ID/AST Systems
- Best Customer Satisfaction
- Best System Performance
- Best Service
2026 ServiceTrak Awards: Blood Culture Systems
- Best Customer Satisfaction
- Best System Performance
- Best Service
2026 Best System Performance
- Immunoassay Analyzers
"We are thrilled that IMV and the Science and Medicine Group has recognized bioMérieux for the ninth consecutive year for the continued dedication and excellence of our product management, operations, and customer support teams," said Randy Pritchard, General Manager and Sr. Vice President of Clinical Operations, bioMérieux. "This recognition, across our immunoassay, ID/AST Systems, and Blood Culture Systems offerings, highlights our commitment to pioneering diagnostics in the fight against sepsis and antimicrobial resistance."
ABOUT BIOMÉRIEUX
Pioneering Diagnostics
A world leader in the field of in vitro diagnostics since 1963, bioMérieux is present in 46 countries and serves more than 160 countries with the support of a large network of distributors. In 2025, revenues reached €4.1 billion, with over 94% of sales outside of France.
bioMérieux provides diagnostic solutions (systems, reagents, software and services) which determine the source of disease and contamination to improve patient health and ensure consumer safety. Its products are mainly used for diagnosing infectious diseases. They are also used for detecting microorganisms in agri-food, pharmaceutical and cosmetic products.
www.biomerieux.com.
bioMérieux is listed on the Euronext Paris stock market.
Symbol: BIM – ISIN Code: FR0013280286
Reuters: BIOX.PA/Bloomberg: BIM.FP
SOURCE bioMérieux
The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
4 Stocks to Buy Before They Rise Further
2 Undervalued Stocks to Buy Before They Rebound
The 10 Best Dividend Stocks
12 Best Blue-Chip Stocks to Buy for the Long Term
United States